The estimated Net Worth of Hazel Hunt is at least $6.91 Milhão dollars as of 1 August 2024. Dr Hunt owns over 60,000 units of Corcept Therapeutics Inc stock worth over $5,451,735 and over the last 4 years he sold CORT stock worth over $631,855. In addition, he makes $826,667 as Chief Scientific Officer at Corcept Therapeutics Inc.
Dr has made over 8 trades of the Corcept Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 60,000 units of CORT stock worth $168,600 on 1 August 2024.
The largest trade he's ever made was exercising 60,000 units of Corcept Therapeutics Inc stock on 1 August 2024 worth over $168,600. On average, Dr trades about 28,497 units every 104 days since 2020. As of 1 August 2024 he still owns at least 153,354 units of Corcept Therapeutics Inc stock.
You can see the complete history of Dr Hunt stock trades at the bottom of the page.
Dr. Hazel Hunt Ph.D. is the Chief Scientific Officer at Corcept Therapeutics Inc.
As the Chief Scientific Officer of Corcept Therapeutics Inc, the total compensation of Dr D at Corcept Therapeutics Inc is $826,667. There are 6 executives at Corcept Therapeutics Inc getting paid more, with Joseph Belanoff having the highest compensation of $4,958,970.
Dr D is 61, he's been the Chief Scientific Officer of Corcept Therapeutics Inc since . There are 6 older and 12 younger executives at Corcept Therapeutics Inc. The oldest executive at Corcept Therapeutics Inc is George Baker, 77, who is the Independent Director.
Hazel's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065.
Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson, eVentures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Corcept Therapeutics Inc executives and other stock owners filed with the SEC include: